Engitix Company
Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. EngitixвАЩ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.
Total Funding:
$6.88
Headquarters:
White City Place, London, UK
Funding Status:
Early Stage Venture
Employee Number:
Undisclosed
Investment Stage:
N/A
Last Funding Type:
Series A
Number Of Exists:
Series A
Technology:
Regenerative Medicine
Investor Type:
Company
Founded Date:
2016
Industry:
Biomarkers & Targets